Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP12 | P39900 | 10/20 | 0.60 |
| ▸ | MMP13 | P45452 | 2/20 | 0.47 |
| ▸ | MMP2 | P08253 | 3/20 | 0.42 |
| ▸ | ABL1 | P00519 | 1/20 | 0.42 |
| ▸ | MMP8 | P22894 | 1/20 | 0.42 |
| ▸ | MMP9 | P14780 | 2/20 | 0.40 |
| ▸ | NAMPT | P43490 | 3/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | ULK1 | O75385 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6462005 | 0.80 | MMP12 (0.66) | MMP12MMP13 | |
| SCHEMBL6463535 | 0.80 | MMP12 (0.88) | MMP12MMP13MMP2ABL1MMP8 | |
| SCHEMBL6451716 | 0.78 | MMP12 (0.81) | MMP12MMP13MMP2ABL1MMP8 | |
| SCHEMBL8337541 | 0.76 | MMP12 (0.76) | MMP12MMP13MMP2ABL1MMP8 | |
| SCHEMBL6882612 | 0.76 | MMP12 (0.82) | MMP12MMP13MMP2ABL1MMP8 | |
| SCHEMBL6882610 | 0.76 | MMP12 (0.82) | MMP12MMP13MMP2ABL1MMP8 | |
| SCHEMBL6369582 | 0.75 | MMP12 (1.00) | MMP12MMP13MMP2ABL1MMP8 | |
| SCHEMBL6879815 | 0.75 | MMP12 (1.00) | MMP12MMP13MMP2ABL1MMP8 | |
| SCHEMBL6881318 | 0.75 | MMP12 (0.82) | MMP12MMP13MMP2ABL1MMP8 | |
| SCHEMBL6451855 | 0.75 | MMP12 (0.60) | MMP12MMP13MMP2ABL1MMP8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040072871-A1 | Novel thiophene derivatives, their process of preparation and the pharmaceutical compositions which comprise them | WARNER-LAMBERT COMPANY LLC | 2004-04-15 | — | — | US | claimed |
| US-20040072871-A1 | Novel thiophene derivatives, their process of preparation and the pharmaceutical compositions which comprise them | WARNER-LAMBERT COMPANY LLC | 2004-04-15 | — | — | US | disclosed |
| WO-2004018448-A1 | NOVEL THIOPHENE DERIVATIVES, PREPARATION METHOD THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME | WARNER-LAMBERT COMPANY LLC (US) | 2004-03-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040072871-A1 | Novel thiophene derivatives, their process of preparation and the pharmaceutical compositions which comprise them | MMP11, MMP13, CBR1 | MMP12 7/4885MMP13 2/4885MMP2 14/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.